Absolutely I can see it. I can see its opposite too. I'm an investor experienced in biotech, I don't wear tinted glasses. And even "good" results won't be proof, just a really good sign. I should add that ambiguous or "bad" results won't be proof either. AD is complex, and it could mean we don't have the right protocols, or the right combo, or... Etc.
I think 2-73 is having too much pre-clinical success to dismiss it as neuronically inert. And the anecdotal AD improvements we've heard are intriguing. But we are developing a CNS therapy, not a magic bean. Patients and vigilance. Ignore the pumping and the bashing.